Tharimmune Appoints Radkowski COO, CEO Wendland Named Chairman

Tharimmune (NASDAQ:THAR) announced on February 7, 2026, the appointment of Michael Radkowski as Chief Operating Officer and the designation of Dr. John Wendland as Chairman of the Board. The leadership changes follow the company's recent strategic pivot to accelerate clinical trials and expand its pipeline of immuno-oncology therapies. Radkowski, previously vice president of operations, will oversee day-to-day operations and resource allocation, while Wendland will provide strategic direction and board oversight. The company cited the changes as a step to strengthen its executive team and improve execution efficiency.